Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Endo Health Solutions Inc. (NASDAQ:ENDP) said FDA issued a complete response letter for a resubmitted NDA for Aveed testosterone to treat
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury